319 patients prescribed Methotrexate (MTX) for diagnosed rheumatoid arthritis were genotyped for several SNP’s involved in the folic acid pathway (folylpoly-gamma-glutamate synthetase (FPGS), gamma-glutamyl hydrolase (GGH),MTHFR A1298C + C677T)) to establish their association with MTX + significant adverse events. The results demonstrated the dosing of MTX in the presence of the A1298C mutation was associated with a 3.05 increased risk of adverse events, with the study concluding these SNPs may indicate a susceptibility to MTX toxicity. Information pertaining to the study’s location, presence of a control group, ethnicity studied + mean age/ gender distribution was not available via the abstract, leading to gaps in the understanding + analysis of this research.
